Ang-(1-7) effects at central level in animal models of cardiovascular disease
| Animal model | Main finding | References |
|---|---|---|
| Transgenic hypertensive rats (mRen2)27 | ICV administration of Ang-(1-7) for 14 days:- decreased systolic and diastolic blood pressure- stabilized the baroreflex control of heart rate, reestablished cardiac autonomic balance, reversed cardiac hypertrophy, and reduced the altered ratio of cardiac Ang II/Ang-(1-7)- attenuated the rise in atrial natriuretic peptide, brain natriuretic peptide, collagen I, fibronectin and TGF-β cardiac expression | Kangussu et al., 2015 [88] |
| DOCA-salt hypertensive rats | ICV administration of Ang-(1-7) for 14 days:- decreased mean blood pressure- enhanced baroreflex bradycardia sensitivity indexes, improved the balance of cardiac autonomic tone and stabilized left ventricular mRNA expression of collagen type I | Guimaraes et al., 2012 [89] |
| Rats with fructose-induced metabolic syndrome | ICV administration of Ang-(1-7) for 4 weeks:- stabilized blood pressure levels- decreased cardiac sympathetic tone baroreflex sensitivity, reduced glucose and insulin levels and enhanced glucose tolerance | Guimaraes et al., 2014 [120] |
| Female rats with aldosterone/NaCl induced hypertension | - ICV infusion of the MasR selective antagonist A-779 exacerbated the increase in blood pressure | Xue et al., 2013 [89] |
| Two-kidney, one clip (2K1C)-operated rats with renovascular hypertension | - Ang-(1-7) injection into RVLM increased the renal sympathetic nerve activity and arterial pressure | Li et al., 2015 [122] |
| Rats with stress-induced hypertension | - Ang-(1-7) microinjection into RVLM increased blood pressure | Du et al., 2013 [123] |
TGF-β: Transforming growth factor beta
